In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

From a valuation perspective, the stock appears undervalued, suggesting a compelling entry point for investors. We believe there’s minimal cause for long-term concern with REGN stock ...

The decision follows recent challenges faced by the company, including the failure of itepekimab and ongoing issues ... stock decline, but analysts still see long-term value in Regeneron’s ...

The stock’s decline was notably more severe than that of its partner, Sanofi (NASDAQ:SNY), which experienced a 6% drop. Bernstein SocGen analysts highlighted concerns about Regeneron’s ability ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...

The S&P 500 eked out a gain of less than 0.1% on Wednesday, June 4, 2025, as soft results from a private payroll report ...

EVGo shares, however, have doubled in the last 12 months and have gained nearly 60% in the last three months, far outpacing the S&P 500 index SPX in both time frames.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc. (MA), Verizon ...